Microtubule Associated Protein 1A (MAP1A)
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Microtubule Associated Protein 1A Protein</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Microtubule Associated Protein 1A</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>MAP1A</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P78527</td>
</tr>
<tr>
<td class="label">PDB Structure</td>
<td>Not determined (large protein)</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~300 kDa</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>2,678 amino acids</td>
</tr>
<tr>
<td class="label">Subcellular Location</td>
<td>Axons, Dendrites, Microtubules, Synapses</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>MAP1 Family</td>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">[Hippocampus](/brain-regions/hippocampus)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cerebral [Cortex](/brain-regions/cortex)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>High</td>
</tr>
<tr>
<td class="label">Substantia Nigra</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Spinal Cord</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Peripheral nerves</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Microtubule stabilization</td>
<td>Small molecule stabilizers</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>MAP1A expression</td>
</tr>
<tr>
<td class="label">Kinase inhibitors</td>
<td>Reduce pathological phosphorylation</td>
</tr>
<tr>
<td class="label">Neurotrophic factors</td>
<td>Enhance MAP1A expression</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
Introduction
MAP1A (Microtubule Associated Protein 1A) is a neuron-specific cytoskeletal protein that plays essential roles in microtubule stabilization, neuronal morphology, synaptic function, and intracellular transport. As part of the MAP1 family, MAP1A is critical for maintaining proper neuronal architecture and function. Dysregulation of MAP1A has been implicated in neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and Huntington's disease.
Overview
MAP1A is one of the largest neuronal proteins and is expressed exclusively in [neurons](/entities/neurons). It is developmentally regulated, with highest expression during synaptogenesis and in mature neurons.
Structure
MAP1A has a distinctive multi-domain structure:
N-terminal Region
- LC1 domain: Light chain 1 binding region
- Projectin-like domains: Involved in protein-protein interactions
- Multiple alpha-helical regions: Structural support
Microtubule-binding Region
- Basic repeats: Multiple microtubule-binding motifs
- Phosphorylation sites: Regulation of binding affinity
- C-terminal region: Mediates homodimerization
Post-translational Modifications
- Phosphorylation: Multiple serine/threonine kinases (PKA, CaMKII, GSK3β)
- Acetylation: Affects microtubule binding
- Sumoylation: Regulation of protein function
Biological Functions
Microtubule Stabilization
MAP1A binds to and stabilizes microtubules:
- Polymerization promotion: Facilitates microtubule assembly
- Protection from depolymerization: Prevents cold-induced disassembly
- Motor protein interaction: Links organelles to microtubules
- Axonal transport: Enables fast axonal transport
Neuronal Morphology
MAP1A is essential for proper neuronal shape:
- Axon guidance: Supports axonal outgrowth
- Dendritic arborization: Maintains dendritic complexity
- Synapse formation: Involved in synaptic development
- Cytoskeletal organization: Overall neuronal architecture
Synaptic Function
MAP1A participates in synaptic processes:
- Presynaptic function: Regulates synaptic vesicle transport
- Postsynaptic density: Associated with postsynaptic structures
- Synaptic plasticity: Involved in activity-dependent remodeling
- Neurotransmitter release: Modulates release machinery
Role in Neurodegeneration
Alzheimer's Disease
MAP1A is significantly implicated in Alzheimer's disease pathogenesis:
- [Tau](/proteins/tau) relationship: Competes with [tau](/proteins/tau) for microtubule binding sites
- Amyloid interaction: Altered expression in AD brain tissue
- Synaptic loss: MAP1A reduction correlates with synapse loss
- Microtubule dysfunction: Contributes to transport deficits
- Neurofibrillary tangles: Altered phosphorylation in tauopathies
Research has shown decreased MAP1A expression in AD hippocampus and cortex, correlating with disease severity.
Parkinson's Disease
MAP1A plays several roles in PD:
- Dopaminergic neuron vulnerability: Reduced MAP1A in substantia nigra
- [Alpha-synuclein](/proteins/alpha-synuclein) interaction: May affect Lewy body formation
- Transport deficits: Contributes to axonal transport impairment
- Mitochondrial trafficking: Dysregulated organelle transport
Huntington's Disease
- Mutant [huntingtin](/proteins/huntingtin-protein) effects: MAP1A cleavage by mutant [huntingtin](/genes/htt)
- Cytoskeletal disruption: Contributes to neuronal dysfunction
- Transport impairment: Axonal transport deficits
Amyotrophic Lateral Sclerosis (ALS)
- Motor neuron degeneration: Altered MAP1A in ALS models
- Axonal transport defects: Similar to other neurodegenerative diseases
- [TDP-43](/proteins/tdp-43) pathology: Relationship with ALS-specific pathology
Expression Pattern
MAP1A expression is neuron-specific and developmentally regulated, with peak expression during synaptogenesis.
Therapeutic Implications
Interacting Proteins
- [Tau](/proteins/tau) (MAPT): Competes for microtubule binding
- MAP1B: Related microtubule-associated protein
- LC1 (MAP1S): Light chain component
- Kinesin motors: Transport along microtubules
- Dynein: Retrograde transport
- [Amyloid-beta](/proteins/amyloid-beta) (APP): Pathological interactions
See Also
- [MAP1A Gene](/proteins/map1a-protein)
- [MAP1B Gene](/proteins/map1b-protein)
- [Tau Protein](/proteins/tau)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Cytoskeleton](/mechanisms/cytoskeleton-dysfunction)
Background
The study of Microtubule Associated Protein 1A Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
- [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
- [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data
References
<sup>[1]</sup> Tucker RP. The roles of microtubule-associated proteins in brain morphogenesis. Prog Neurobiol. 1990;35(5):351-361. PMID: 2134109(https://pubmed.ncbi.nlm.nih.gov/2134109/).
<sup>[2]</sup> Gonzalez-Billault C, et al. MAP1A expression in brain development and neurodegeneration. J Neurosci Res. 2002;70(5):656-666. PMID: 12424577(https://pubmed.ncbi.nlm.nih.gov/12424577/).
<sup>[3]</sup> Harada A, et al. Microtubule-associated protein 1A in neuronal function. Neurosci Res. 2002;44(1):1-12. PMID: 12216570(https://pubmed.ncbi.nlm.nih.gov/12216570/).
<sup>[4]</sup> Veeranna, et al. Phosphorylation of MAP1A in Alzheimer's disease. J Neurochem. 2008;105(3):917-927. PMID: 18182064(https://pubmed.ncbi.nlm.nih.gov/18182064/).
<sup>[5]</sup> Chen J, et al. MAP1A and neurodegeneration. Cell Mol Neurobiol. 2020;40(8):1247-1260. PMID: 32107745(https://pubmed.ncbi.nlm.nih.gov/32107745/).
<sup>[6]</sup> Yu Y, et al. Axonal transport deficits in neurodegenerative diseases. J Neurochem. 2021;158(2):222-238. PMID: 33503218(https://pubmed.ncbi.nlm.nih.gov/33503218/).